Clinical trials
Terminated Phase 1/2 trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
1,387 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 9 |
| 2001 | 8 |
| 2002 | 15 |
| 2003 | 25 |
| 2004 | 28 |
| 2005 | 24 |
| 2006 | 39 |
| 2007 | 58 |
| 2008 | 58 |
| 2009 | 69 |
| 2010 | 61 |
| 2011 | 53 |
| 2012 | 50 |
| 2013 | 59 |
| 2014 | 57 |
| 2015 | 85 |
| 2016 | 62 |
| 2017 | 96 |
| 2018 | 98 |
| 2019 | 89 |
| 2020 | 83 |
| 2021 | 104 |
| 2022 | 72 |
| 2023 | 43 |
| 2024 | 21 |
| 2025 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 1,387 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 59 |
| M.D. Anderson Cancer Center | 58 |
| Pfizer | 21 |
| Bristol-Myers Squibb | 20 |
| Incyte Corporation | 18 |
| Fred Hutchinson Cancer Center | 14 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 14 |
| Sanofi | 14 |
| Genmab | 13 |
| Hoffmann-La Roche | 13 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 109 |
| Neoplasms | 89 |
| Breast Neoplasms | 82 |
| Leukemia, Myeloid, Acute | 74 |
| Neoplasm Metastasis | 73 |
| Multiple Myeloma | 70 |
| Melanoma | 65 |
| Recurrence | 57 |
| Ovarian Neoplasms | 55 |
| Prostatic Neoplasms | 53 |
Trials
Showing 1 to 25 of 1,387. Each trial links to its page on Pharma Observatory.
1,287 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.